Biosimilars for Blood Disorder Indications in the US Will Reach More Than US$ 2.4 Billion in 2020

Nov. 16, 2011 - PRLog -- A study undertaken by IMARC Group entitled “Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)” reveals that by 2020, biosimilars for blood disorder indications will reach sales worth more than US$ 2.4 billion in the US. Findings from the study suggest that biosimilar versions of Epogen (Epoetin Alfa) may be launched as early as 2013. This launch is expected to be followed by launches of biosimilar versions of Neupogen (Filgrastim) and Neulasta (Pegfilgrastim).

According to this study, biosimilar versions of Epogen and Neupogen have already been launched in major European markets with their uptake being quite promising in some of these markets. Historical generic adoption rates in the US have been significantly faster than most European markets, furthermore,   a recent survey on US physicians suggested that respondents were quite willing to prescribe biosimilars for blood disorder indications upon their launch in the US. This suggests that the US penetration of biosimilars in the blood disorder indication would be even higher than the European levels.

IMARC’s new report entitled “Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)” provides an analytical and statistical insight into the US biosimilar market. The study, that has been undertaken using desk-based as well as qualitative primary research, provides and draws upon analysis of six aspects of the US biosimilar market.

Key Aspects Analyzed:

Evaluating the Current Market Landscape of Biosimilars:
•   Identification of currently marketed biosimilars and their historical performance
•   Identifying the reasons for the slow uptake of currently marketed biosimilars
•   Analyzing historical data to formulate conclusions on the future growth and market trends of biosimilars

Evaluating the Extent of Price, Sales and Volume Erosions Caused by Biosimilars:
•   Analyzing historical time series data on price, volume and sales erosion in the US & Europe
•   Analyzing previous models and assumptions on price and volume erosion caused by biosimilars
•   Evaluating and comparing price and volume erosion created by biosimilars vis-a-vis by  small molecule generics
•   Evaluating and comparing  price, volume and sales erosion by biosimilars across various biological classes

Evaluating the Market Potential of Biosimilars Across Various Molecules:
Molecules Covered: Somatropin (Genotropin/Humatrope/Other HGH), Epoetin Alfa (Epogen/Eprex), Filgrastim (Neupogen), Pegfilgrastim (Neulasta), Insulin Lispro (Humalog), Insulin Glargine (Lantus), Insulin Detemir (Levemir), Interferon Beta-1A (Avonex), Interferon Beta-1A (Rebif), Interferon Beta-1B (Betaferon), Bevacizumab (Avastin), Trastuzumab (Herceptin), Rituximab (Mabthera/Rituxan), Cetuximab (Erbitux), Etanercept (Enbrel), Infliximab (Remicade), Adalimumab (Humira), Ranibizumab (Lucentis), Omalizumab (Xolair) and Natalizumab (Tysabri).

Focus of the Analysis for Each Molecule:
•   Historical background and overview
•   Historical brand sales
•   Patent position
•   Competing products
•   Biosimilars in pipeline
•   Brand and biosimilar sales forecasts
   
Evaluating the Sales of Biosimilars across Various Indications:
Indications Covered: Immunology & Inflammation, Diabetes, Oncology, Blood Disorders and Growth Deficiency

Focus of the Analysis for Each Indication:
•   Historical brand sales
•   Brand and biosimilar sales forecasts
•   Breakup of  molecules

Evaluating the Biosimilar Competitive Landscape:
•   Identifying branded biological manufacturers that expect the highest amount of erosion from biosimilars
•   Identifying biosimilar manufacturers and their pipelines

Understanding the Current Legislation on Biosimilars:
•   An insight into the Biologics Price Competition and Innovation Act
•   An insight into the key biosimilar issues that still remain unaddressed
•   Interchangeability and Substitutability
•   Data Exclusivity
•   Statutory provisions for dealing with patent litigations

To buy the complete report or to get a free sample, please contact:

IMARC Group Asia
Email: apac@imarcgroup.com
Phone: +91-120-425-6531

IMARC Group North America
Email:  america@imarcgroup.com
Phone: +1-631-791-1145


To know more please visit:  http://www.imarcgroup.com/